TRIM59 Antibody

What is TRIM59 and why is it significant in research?

TRIM59 (Tripartite Motif Containing 59) is a member of the TRIM/RBCC protein family involved in innate immune responses and protein ubiquitination. The significance of TRIM59 in research stems from its roles in regulating inflammation and phagocytosis in macrophages, as well as its potential as a biomarker for multiple cancer types. In humans, the canonical TRIM59 protein has 403 amino acid residues with a mass of 47.1 kDa and is primarily localized to the endoplasmic reticulum . Recent studies have identified TRIM59 as an early signal transducer in oncogene pathways, making it valuable for cancer research .

What are the key considerations when selecting a TRIM59 antibody for research?

When selecting a TRIM59 antibody, researchers should consider:

• Target epitope specificity: Antibodies targeting different regions (N-terminal, C-terminal, internal regions) may yield different results. For instance, antibodies generated against the C-terminal region (like TRIM59#72) have shown greater specificity than those against the N-terminal region containing common RBCC domains shared by TRIM family members .

• Species reactivity: Verify cross-reactivity with your experimental model. Some antibodies react with human, mouse, and rat TRIM59, while others have narrower specificity .

• Application compatibility: Confirm validation for your specific application (Western blot, IHC, IF, etc.) .

• Clonality: Polyclonal antibodies may offer broader epitope recognition, while monoclonal antibodies provide greater consistency between lots .

• Validated literature references: Select antibodies with proven performance in peer-reviewed publications .

How can I validate a TRIM59 antibody before using it in my research?

A systematic validation approach should include:

• Positive and negative controls: Use tissues known to express TRIM59 (e.g., breast cancer tissue has been used as a strong positive control) and appropriate negative controls (PBS instead of primary antibody).

• Western blot analysis: Verify that the antibody detects a protein of the expected molecular weight (approximately 47 kDa). Compare with known TRIM59-expressing cell lines (e.g., Jurkat cells have been used as positive controls) .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm binding specificity.

• Cross-validation with different methods: Compare results from multiple detection methods (e.g., IF, IHC, Western blot) to ensure consistency .

• Knockout/knockdown verification: Use TRIM59 knockout or knockdown models, if available, to confirm antibody specificity .

What are the optimal conditions for using TRIM59 antibodies in immunohistochemistry?

For optimal immunohistochemical (IHC) detection of TRIM59:

• Tissue preparation: Use formalin-fixed, paraffin-embedded sections with proper antigen retrieval. Multiple studies have successfully used this approach for TRIM59 detection .

• Blocking: Employ dual blocking steps using universal blocking reagents (e.g., Power Block) followed by avidin-biotin blocking to minimize background signal .

• Antibody concentration: Titrate between 1:10-1:500 dilution depending on the specific antibody. For paraffin-embedded sections, concentrations of 4-8 μg/ml have proven effective .

• Detection system: Standard ABC (Avidin Biotin Complex) protocol has shown reliable results in multiple studies .

• Counterstaining: Light hematoxylin counterstaining allows for proper visualization of tissue architecture without obscuring DAB signal .

• Scoring method: For research purposes, employ a combined relative score system based on both staining intensity and extent, especially when TRIM59 shows heterogeneous staining patterns across different tissues .

How should I design experiments to study TRIM59's role in immune cell function?

Based on recent research on TRIM59's role in immune function :

• Knockout model design: Generate conditional knockout mice (e.g., Trim59-cKO) using Cre-lox technology to achieve cell-type specific deletion.

• Validation of knockout: Verify TRIM59 deletion at both mRNA and protein levels in target cell populations (e.g., bone marrow-derived macrophages).

• Functional assays:

  • Phagocytosis assays to assess macrophage function

  • Cytokine production measurement after LPS stimulation

  • Assessment of NF-κB pathway activation using phosphorylation status of key proteins (p-IKKα/β, p-IκBα, p-p65)

• In vivo challenge models: CLP (cecal ligation and puncture) surgery has been used to study TRIM59's role in sepsis .

• Flow cytometry panels: Include markers for neutrophils (CD11b+Ly6G+), macrophages (CD11b+F4/80+), dendritic cells (CD11c+), B cells (B220+), and T cells (CD4+, CD8+) to assess immune cell infiltration and population changes .

What methods are recommended for quantifying TRIM59 expression in tumor samples?

For accurate quantification of TRIM59 in tumor samples:

• Tissue microarray approach: This allows for standardized, high-throughput analysis across multiple samples .

• Scoring system: Implement a semi-quantitative scoring system that accounts for:

  • Staining intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong)

  • Extent of staining (percentage of positive cells)

  • Combined scores for comparative analysis

• Blinded evaluation: Have at least two experienced pathologists independently assess immunohistochemical scores to ensure reliability .

• Digital image analysis: Use automated systems to quantify staining intensity and minimize subjective bias .

• Normalization: Compare tumor expression to adjacent normal tissue within the same sample to account for technical variations .

• Cross-validation: Validate IHC results with other quantification methods such as RT-qPCR or western blotting when possible .

How can TRIM59 antibodies be applied in studying cancer progression and prognosis?

TRIM59 antibodies have emerged as valuable tools for cancer research:

What are the current methodologies for investigating TRIM59's involvement in signaling pathways?

To investigate TRIM59's role in signaling pathways:

• Stimulation experiments: Use LPS stimulation on wild-type versus TRIM59-knockout macrophages to assess differences in NF-κB pathway activation .

• Phosphorylation analysis: Monitor phosphorylation status of key signaling proteins (IKKα/β, IκBα, p65) using phospho-specific antibodies at various time points after stimulation .

• Nuclear translocation assays: Measure nuclear translocation of transcription factors like p65 using nuclear/cytoplasmic fractionation followed by western blotting .

• Co-immunoprecipitation studies: Identify TRIM59 interaction partners by performing co-IP experiments followed by mass spectrometry or western blotting for suspected binding partners .

• Ubiquitination assays: As TRIM59 has E3 ubiquitin ligase activity, assess protein ubiquitination status in the presence and absence of TRIM59 .

• Bioinformatics correlation analysis: Utilize datasets like TCGA to correlate TRIM59 expression with immune markers and signaling pathway components .

How can I determine the specific cell types expressing TRIM59 in heterogeneous tissue samples?

For precise determination of TRIM59-expressing cell types:

• Double immunofluorescence staining: Combine TRIM59 antibody with cell-type specific markers:

  • Cytokeratin for epithelial cells

  • CD68 for macrophages

  • CD3 for T cells

  • Other lineage-specific markers as needed

• Confocal microscopy: Use high-resolution confocal imaging to determine subcellular localization and co-localization with other proteins .

• Single-cell analysis approaches: When available, employ single-cell RNA sequencing combined with antibody validation to precisely map TRIM59 expression across cell populations.

• Laser capture microdissection: Isolate specific cell populations from tissue sections for downstream analysis of TRIM59 expression .

• In situ hybridization combined with IHC: Perform RNA-FISH for TRIM59 mRNA combined with IHC for cell-type markers to confirm expression at both mRNA and protein levels.

How can I address specificity concerns when working with TRIM59 antibodies?

When addressing specificity concerns:

• Antibody selection criteria: Choose antibodies raised against unique regions of TRIM59. Research has shown that antibodies generated against C-terminal regions (e.g., TRIM59#72) exhibit greater specificity than those targeting N-terminal RBCC domains common to the TRIM family .

• Validation controls:

  • Use TRIM59 knockout/knockdown samples

  • Perform peptide competition assays

  • Compare results with multiple antibodies targeting different epitopes

• Cross-reactivity assessment: Test antibodies on tissues from different species to confirm specificity. Western blots should show a single band at the expected molecular weight (approximately 47-53 kDa) .

• Literature verification: Compare your findings with published results using the same antibody.

• Recombinant protein controls: Use purified recombinant TRIM59 protein as a positive control in western blot analyses .

What are the common pitfalls in interpreting TRIM59 immunohistochemistry results in cancer studies?

Researchers should be aware of these interpretation challenges:

• Heterogeneous expression patterns: TRIM59 may show variable expression within the same tumor, requiring assessment of multiple fields (at least four per section) at 200× magnification .

• Subcellular localization variability: TRIM59 is primarily cytoplasmic in most tumors, but some studies report nuclear staining. This variability should be considered when scoring results .

• False positive signals: Some commercial antibodies generated against oligopeptides may not detect true TRIM59 protein, necessitating thorough validation .

• Background staining issues: Proper blocking protocols are essential, as incomplete blocking can lead to false positive signals, especially in tissues with high endogenous biotin like liver or kidney .

• Correlation with clinical parameters: When correlating TRIM59 expression with clinical outcomes, multivariate analysis should be performed to account for confounding factors .

• Scoring system standardization: The lack of standardized scoring systems across studies can complicate result comparisons, so detailed methodology reporting is crucial .

How is TRIM59 antibody-based research contributing to our understanding of cancer immunotherapy?

TRIM59 research is expanding our understanding of cancer immunotherapy through:

• Immune checkpoint correlation: Studies have found significant correlations between TRIM59 expression and immune checkpoint markers, suggesting potential implications for immunotherapy response prediction .

• Tumor mutation burden relationships: TRIM59 expression has shown significant correlation with tumor mutation burden specifically in lung adenocarcinoma, which could inform immunotherapy strategies .

• Immune cell infiltration analysis: TRIM59 expression correlates with specific immune cell populations, particularly neutrophils and dendritic cells, which play crucial roles in immunotherapy efficacy .

• Stromal component interaction: Significant correlations between TRIM59 expression and stromal scores suggest influence on the tumor microenvironment, potentially affecting immunotherapy outcomes .

• NF-κB pathway modulation: TRIM59's role in regulating the NF-κB pathway, which is central to inflammation and immune responses, points to potential mechanisms affecting immunotherapy response .

What are the current methodologies for investigating TRIM59's E3 ubiquitin ligase activity and its downstream targets?

To study TRIM59's E3 ubiquitin ligase function:

• In vitro ubiquitination assays: Reconstitute ubiquitination reactions using purified components (E1, E2, TRIM59, substrate protein, ubiquitin, ATP) to directly assess E3 ligase activity.

• Substrate identification approaches:

  • Immunoprecipitation coupled with mass spectrometry

  • Proximity labeling methods (BioID, APEX)

  • Protein microarray screening

• Ubiquitin chain linkage analysis: Use linkage-specific antibodies or mass spectrometry to determine the type of ubiquitin chains (K48, K63, etc.) formed by TRIM59, which can indicate the fate of substrates (degradation vs. signaling).

• Structure-function analysis: Generate TRIM59 mutants lacking specific domains (RING finger, B-box, coiled-coil) to determine their contribution to E3 ligase activity and substrate recognition.

• Proteasome inhibition studies: Compare protein levels of potential substrates with and without proteasome inhibitors in the presence and absence of TRIM59.

How can researchers integrate TRIM59 antibody-based assays with multi-omics approaches for comprehensive functional studies?

For integrated multi-omics studies involving TRIM59:

• Combined proteomics and transcriptomics:

  • Compare TRIM59 protein levels (detected by antibodies) with mRNA expression

  • Identify post-transcriptional regulation mechanisms

  • Validate findings from large-scale datasets like TCGA

• Spatial transcriptomics integration:

  • Correlate TRIM59 antibody staining patterns with spatial transcriptomics data

  • Map TRIM59 expression to specific tissue microenvironments

• Phosphoproteomics combination:

  • Use TRIM59 antibodies for immunoprecipitation followed by phosphoproteomic analysis

  • Identify signaling networks affected by TRIM59 expression or knockout

• Single-cell multi-omics approaches:

  • Combine single-cell RNA-seq with antibody-based protein detection

  • Profile TRIM59 expression patterns across heterogeneous cell populations

• Systems biology framework:

  • Incorporate antibody-derived TRIM59 expression data into pathway analysis

  • Model TRIM59's impact on cellular networks using quantitative antibody-based measurements

  • Validate computational predictions with functional assays

Data Tables

Table 3: Recommended Conditions for TRIM59 Antibody Applications